New York Stock Exchange (NYSE) · Healthcare
Novo Nordisk A/S NVO
SpeculativeScore band: 40–50
The thesis, in one sentence
A high-quality pharmaceutical business with strong margins and returns on capital, but with competitive erosion against its main rival confirmed in the company's own filings, and no real margin of safety at the current price.
Written for this site in plain English, without figures. The arithmetic is in the full report.
The thesis is from the deep report of 2026-07-18; the verdict badge reflects the latest scoring of 2026-09-06.
Key risks
- Market share in its core class is being lost to a single competitor
- A foundation controls the votes with a much smaller economic stake
- Reversion to the historical multiple is not a valid anchor while share erodes
What would change the verdict
- Net margin falls for two consecutive quarters, ending the quality case
- Revenue growth falls for two consecutive quarters as share loss continues
- The multiple re-rates upward without the erosion stopping
- Total market growth fails to offset the loss of relative share
Read it yourself
Step five of the method is the reader's: open the latest annual or quarterly report and read it before acting on anything here. A score is a summary, and a summary is not understanding.
Next report expected 2026-11-04. The deep report was written against the filings available on 2026-07-18; anything published since is not in it.
Price, one year
DCF valuation range
range of the DCF modelsbase casetoday's price
Valuation range, shape only. Figures in the full version.
Monte Carlo outcome shape
scenarios below today's pricescenarios above today's pricetoday's price
Distribution of simulated outcomes around today's price. Bar heights only; the scale and the percentiles are in the full version.
Where the money goes
Last four reported quarters, 2025-06 → 2026-03. Filings data as gathered on 2026-07-18. Figures rounded to three significant digits.
Chapter one: Executive summary
Deep-value report: Novo Nordisk A/S (NVO) — 2026-07-18
Currency convention: operational figures (revenue, profit, EPS, cash flow) are reported in DKK (Danish kroner), the company's official reporting currency per the 20-F/6-K. The share price, market cap and multiples are in USD (ADR NVO, NYSE). Conversion rate used: …/USD (July 2026 average, source: X-Rates/valutafx). Reference price: … (July 17, 2026, source: stockanalysis.com).
Executive summary
Thesis. Novo Nordisk is the historical leader of the GLP-1 market (Ozempic, Wegovy, Rybelsus) — a franchise with exceptional margins (net margin 33%, ROIC ~38%) and a moat built on patents, manufacturing scale and prescriber relationships. But 2025 was the year the "quality compounder, buy any dip" thesis broke down: the company itself acknowledges in its 20-F that it lost the leading position to Eli Lilly in both Ozempic (diabetes) and Wegovy (obesity) during 2025 (source: NVO 20-F 2026-02-04, Item 4.B); it cut growth guidance three times in six months; it changed CEOs under direct pressure from the majority shareholder (Novo Nordisk Foundation); it announced the layoff of ~9,000 employees (~11% of the workforce); and it completely suspended the share buyback program in the very year the stock fell ~65% from its peak (source: agent research 6-K, TradingNews).
Estimated value. A conservative DCF (growth 4… in the early years, FCF margin normalizing gradually to 25% as the capex supercycle winds down) gives a base value of ~…/share, with a range of … (bear) – … (bull) across the three scenarios. Earnings Power Value (EPV, no growth, using normalized EBIT) gives …-49/share. Both methods anchored in real cash flow converge very close to the current price of … — meaning no real margin of safety in the conservative scenario. Reversion to the historical 5-year multiple (average P/E 30x) would give a much higher value (…+), but that multiple was set during a period of 20%+/year growth with no serious competition — using it as an anchor today would be a methodological error, not a signal of undervaluation.
Verdict. This is NOT yet a "buy without discussion" opportunity despite the massive price decline. The quality of the underlying business remains excellent (ROIC 38%, gross margin 81%, real patent moat through 2031-2032), but the competitive deterioration is confirmed by the company itself, not just market perception, and at the current price there is no sufficient discount to a conservative valuation. The recalculated GBL score is 43.3% (SPECULATIVE), significantly below the tracker score (63.3%, INTERESTING) — see the final section for the explanation of the divergence.
Figures were removed from this excerpt. The full report opens free for five tickers a week — see what's open now.
Full report contents
- Executive summary
- 🔒 The business and the moat (Available in the full report)
- 🔒 Management and capital allocation (Available in the full report)
- 🔒 What changed over the last 4 quarters (Available in the full report)
- 🔒 Accounting red flags (Available in the full report)
- 🔒 Triangulated valuation (Available in the full report)
- 🔒 Pre-mortem: why the thesis could be wrong (Available in the full report)
- 🔒 Verdict compared to the tracker's GBL score (Available in the full report)
Evaluation history
| Date | Verdict |
|---|---|
| 2026-07-12 | Interesting |
| 2026-07-18 | Speculative |
| 2026-09-06 | Speculative |
Want the rest of this report?
Subscribe to get one full deep report a week by email, the day before it opens on the site.